Cancer Cell Visualization
Advanced Cancer Risk Assessment

GeneCancerHereditary Risk Analysis

Comprehensive genetic testing analyzing 108+ genes associated with hereditary cancer syndromes. Get personalized screening recommendations and evidence-based prevention strategies.

BRCA1/2 TestingLynch SyndromeColorectal CancerProstate CancerMelanomaPancreatic Cancer
CLIA Certified Lab
HIPAA Compliant
CE-IVD Certified
Explore
108+
Genes Analyzed
One of the largest hereditary cancer panels
15+
Cancer Types
Breast, colon, prostate, melanoma & more
99.9%
Accuracy
CLIA-certified NGS sequencing
2-3 Weeks
Results
From lab receipt to your full report
Comprehensive Cancer Analysis

Every Major Hereditary
Cancer Risk, Covered

GeneCancer doesn't screen for one type — it analyzes 108+ genes across all major hereditary cancer syndromes so nothing is missed.

Breast & Ovarian Cancer
12 genes

Breast & Ovarian Cancer

BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C, RAD51D

Lynch Syndrome & Colorectal
14 genes

Lynch Syndrome & Colorectal

MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH

Prostate Cancer
8 genes

Prostate Cancer

HOXB13, BRCA2, ATM, CHEK2, BRCA1

Melanoma & Skin Cancer
7 genes

Melanoma & Skin Cancer

CDKN2A, CDK4, BAP1, MC1R, MITF

Li-Fraumeni & Rare Syndromes
9 genes

Li-Fraumeni & Rare Syndromes

TP53, PTEN, CDH1, STK11, SMAD4

Pancreatic & Gastric Cancer
8 genes

Pancreatic & Gastric Cancer

BRCA2, ATM, PALB2, CDKN2A, CDH1, STK11

Questions Families Ask

Your Family History Has
Answers In Your Genes

If cancer has appeared in your family tree, you deserve to know whether you inherited that risk — and exactly what to do about it.

"My mother had breast cancer. Am I at risk?"

Family history is one of the strongest indicators of hereditary cancer risk — and genetics can tell you exactly how much.

"My mother had breast cancer. Am I at risk?"
BRCA1 / BRCA2

What the Science Says

BRCA1 and BRCA2 mutations are inherited — if your mother had breast or ovarian cancer caused by a BRCA mutation, you have a 50% chance of carrying the same mutation. Women with BRCA1 mutations have up to a 72% lifetime breast cancer risk compared to 12% in the general population.

How GeneCancer Helps

GeneCancer analyzes BRCA1, BRCA2, PALB2, ATM, CHEK2, and 9 more breast cancer genes — giving you and your doctor a complete hereditary risk picture to build a proactive surveillance plan.

BRCA mutations account for 5-10% of all breast cancers but up to 25% of hereditary cases

"Multiple family members have had colon cancer. Should I be worried?"

When colon cancer runs through families, Lynch Syndrome is often behind it — and it's one of the most actionable genetic diagnoses you can have.

"Multiple family members have had colon cancer. Should I be worried?"
MLH1 / MSH2 / MSH6

What the Science Says

Lynch Syndrome is the most common hereditary colorectal cancer syndrome, caused by mutations in DNA mismatch repair genes. People with Lynch Syndrome have up to an 80% lifetime colon cancer risk — but with proper surveillance (colonoscopy every 1-2 years starting at 20-25), most Lynch Syndrome-related cancers are found early and treated successfully.

How GeneCancer Helps

GeneCancer tests all five Lynch Syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) and provides a personalized colonoscopy schedule if a mutation is found.

Lynch Syndrome affects 1 in 279 people but is diagnosed in only 5% of those who have it

"I'm a man. Do I really need hereditary cancer testing?"

Absolutely. Men carry BRCA mutations and face elevated cancer risks from them — and several hereditary cancer genes affect men just as significantly.

"I'm a man. Do I really need hereditary cancer testing?"
BRCA2 / HOXB13 / ATM

What the Science Says

Men with BRCA2 mutations have a 7% lifetime risk of breast cancer (vs. 0.1% normally) and up to 27% risk of prostate cancer by age 80. The HOXB13 gene dramatically raises aggressive prostate cancer risk. Lynch Syndrome in men raises colorectal, stomach, and urothelial cancer risk. These aren't just women's issues.

How GeneCancer Helps

GeneCancer's male-specific reporting highlights prostate cancer risk genes, Lynch Syndrome variants, and BRCA2 — with PSA screening recommendations tailored to your specific genetic profile.

Men with BRCA2 mutations are 8x more likely to develop prostate cancer before age 65

Knowledge is not fear — it's your most powerful prevention tool.

Know Your Hereditary Risk
Real Families. Real Discoveries.

The Gene That Changed
Everything

These aren't just stories — they're proof that hereditary cancer testing saves lives. Not someday. Now.

Rachel K.
Gene Discovery
BRCA2 Pathogenic Variant
Inherited from her father's side — often overlooked
Rachel K.
41, Seattle, WA • Teacher & Mother of Two

"Both my grandmother and aunt had breast cancer, but everyone assumed it was my mother's side we had to worry about. GeneCancer revealed I carry a BRCA2 mutation — from my dad. My sister tested positive too. We both started annual MRI screening. Eight months later, my sister's MRI caught a Stage 1 tumor that was completely invisible on mammography."

The Outcome

Stage 1 tumor caught. Lumpectomy, no chemotherapy needed. My sister is healthy today — and credits the test with saving her life.

David M.
Gene Discovery
MLH1 Pathogenic Variant (Lynch Syndrome)
His father and uncle both died from colon cancer in their 50s
David M.
48, Atlanta, GA • Attorney, Lynch Syndrome Advocate

"My dad and his brother both died of colon cancer before age 55. I was 46 when I finally did the test. They found an MLH1 mutation — Lynch Syndrome. My gastroenterologist immediately scheduled a colonoscopy. They removed three pre-cancerous polyps that were already there. Without that test, I might have waited until symptoms showed up."

The Outcome

Three pre-cancerous polyps removed. Now on annual colonoscopy surveillance. No cancer — and I intend to keep it that way.

Priya S.
Gene Discovery
PALB2 Pathogenic Variant
Not BRCA — but carries similar breast cancer risk elevation
Priya S.
35, Chicago, IL • Software Engineer

"No obvious cancer history in my family, but my OB/GYN suggested genetic testing because I'm of South Asian descent and there are some hereditary patterns worth screening for. GeneCancer found a PALB2 mutation — which I'd never even heard of. It gives me a 35-58% lifetime breast cancer risk. I was 35. No one would have screened me for another decade without this test."

The Outcome

Started MRI surveillance at 35 instead of 40+. My oncologist says catching this early gives me the best possible options throughout my life.

108+
Genes Analyzed
15+
Cancer Types Covered
28,000+
Reports Delivered
4.9/5
Patient Rating
Pricing Plans

Choose YourProtection Plan

Select the cancer screening package that best fits your health goals and family needs

MonthlyAnnualSave 20%

Essential

$125 one-time kit fee

$69/month
  • GeneCancer screening panel
  • BRCA1/2 analysis
  • Basic hereditary risk report
  • Digital report access
  • Email support
  • Screening recommendations
Most Popular

Premium

$125 one-time kit fee

$89/month
  • Everything in Essential +
  • 108+ cancer gene analysis
  • Lynch Syndrome testing
  • Detailed screening plan
  • Family risk assessment
  • Genetic counselor consultation
  • Priority 48-hour processing
  • Risk comparison report

Family

$125 one-time kit fee

$139/month
  • Everything in Premium +
  • Coverage for up to 4 people
  • Bi-annual screening for all
  • Family genetic risk mapping
  • Shared family dashboard
  • Dedicated account manager
  • Lifetime report updates
  • Prevention plan monitoring
HIPAA Compliant
256-bit Encryption
30-Day Money Back
24/7 Support
Real Sample Data

Sample Report

Explore a real GeneCancer report with comprehensive cancer risk analysis and personalized recommendations

Report ID: GC-2024-789456

Sample Report — For Demonstration Purposes

Report Date
2024-01-15
Sample Collected
2023-12-28
Lab ID
LAB-GC-45678
Ethnicity
European
108
Genes Analyzed
12
Variants Detected
3
Elevated Risk
5
Moderate Risk
8
Actionable Insights

Breast & Ovarian

Overall Risk:
Elevated
BRCA1
Variant: c.5266dupC
RS ID: rs80357906
Genotype: Heterozygous
High Impact
Pathogenic variant in BRCA1 gene significantly increases lifetime risk of breast cancer (up to 72%) and ovarian cancer (up to 44%). This variant disrupts DNA repair mechanisms.
Recommendation
Enhanced screening protocol recommended: Annual breast MRI starting age 25-30, mammography starting age 30, consider risk-reducing strategies. Genetic counseling strongly advised for family planning.
PALB2
Variant: c.3113G>A
RS ID: rs45551636
Genotype: Heterozygous
Moderate Impact
Likely pathogenic variant in PALB2 gene associated with 2-4x increased breast cancer risk. PALB2 partners with BRCA2 in DNA repair.
Recommendation
Annual mammography and clinical breast exams starting age 30. Consider supplemental breast MRI screening. Discuss with oncologist regarding preventive options.
ATM
Variant: c.5762-1050A>G
RS ID: rs1801516
Genotype: Heterozygous
Low-Moderate Impact
Variant of uncertain significance in ATM gene. May contribute to moderately increased breast cancer risk (1.5-2x). ATM is involved in cell cycle checkpoint control.
Recommendation
Standard screening with annual mammography starting age 40, or 10 years before earliest family diagnosis. Monitor research updates on this variant.

Screening Recommendations

Breast Cancer
Annual MRI age 25-30, Annual mammography age 30+
Starting age: 25-30 years
Ovarian Cancer
Transvaginal ultrasound + CA-125 every 6 months
Starting age: 30-35 years
Colorectal Cancer
Colonoscopy every 1-2 years
Starting age: 10-12 years (APC), 20-25 years (Lynch)
Prostate Cancer
PSA + DRE annually
Starting age: 40 years

Cancer Risk Comparison

Breast Cancer
Population:
12.5%
Your Risk:
45-72%
Ovarian Cancer
Population:
1.3%
Your Risk:
25-44%
Colorectal Cancer
Population:
4.3%
Your Risk:
70-90%
Prostate Cancer
Population:
12.5%
Your Risk:
30-40%

Get the Complete Report

Download the full report with all findings, screening recommendations, risk comparisons, and prevention strategies

Simple 4-Step Process

From Home to
Life-Saving Clarity

Getting your hereditary cancer risk profile is easier than scheduling a doctor's appointment — and far more powerful.

Your Kit Ships to Your Door
1
Step 1

Your Kit Ships to Your Door

A lab-grade DNA collection kit arrives within 2-3 business days. Inside: a sterile saliva collection tube, clear instructions, and a prepaid return envelope. No lab visit. No needle. No hassle.

Free two-way shipping. Kit arrives in 2-3 business days.
A 2-Minute Saliva Sample at Home
2
Step 2

A 2-Minute Saliva Sample at Home

Just spit into the collection tube — that's it. No needles, no clinic visits, no appointments. Cap it, seal the prepaid envelope, and drop it in any mailbox. Your DNA travels safely to our lab.

Takes less than 2 minutes. Works from anywhere in the US.
Our Lab Analyzes 108+ Cancer Genes
3
CLIA Certified
CAP Accredited
CE-IVD Certified
MD Reviewed
Step 3

Our Lab Analyzes 108+ Cancer Genes

Your sample is processed in our CLIA-certified, CAP-accredited laboratory using Illumina next-generation sequencing — the same technology used by major cancer centers. Board-certified geneticists review every finding before your report is released.

Your Personalized Report — Yours for Life
4
Step 4

Your Personalized Report — Yours for Life

In 2-3 weeks, receive a comprehensive, easy-to-read cancer risk report covering all 15+ cancer types. Share it with any oncologist, gynecologist, or primary care physician. Your results never expire — your DNA doesn't change.

Available as app report and downloadable PDF. Share with any provider.

Results in 2-3 Weeks

Information that protects you and your family for a lifetime.

Frequently Asked Questions

Everything you need to know about GeneCancer

GeneCancer is recommended for individuals with a family history of cancer, multiple cancer diagnoses in the family, cancer at young ages, or specific cancer types like breast, ovarian, or colorectal cancer. It's also valuable for anyone wanting proactive insight into their hereditary cancer risk.
We analyze 108+ genes including BRCA1, BRCA2, PALB2, ATM, CHEK2, Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), TP53, PTEN, APC, CDKN2A, STK11, and many others associated with hereditary cancer syndromes covering 15+ cancer types.
Our test has 99.9% analytical accuracy and is performed in CLIA-certified, CE-IVD Certified laboratories using Illumina next-generation sequencing technology. All results are reviewed by board-certified geneticists before release.
Many insurance plans cover genetic testing for individuals who meet specific criteria (family history, personal cancer history). We provide detailed documentation to help with insurance reimbursement and our team can help verify your coverage.
A positive result means you have an increased risk for certain cancers. You'll receive personalized screening recommendations, prevention strategies, and can consult with a genetic counselor. Many hereditary cancers are highly preventable with proper surveillance.
We use 256-bit encryption for all data transmission and storage. Your genetic information is never shared with third parties without explicit consent. We are fully HIPAA and GDPR compliant, and you can request data deletion at any time.
Protecting Families Through Genetic Knowledge
Join 28,000+ Families Who Know Their Risk

Stop Wondering.
Start Protecting.

You can't change your genes — but you can change what happens next. GeneCancer gives you the knowledge to protect yourself and the family you love.

Covered by many insurance plans. HSA/FSA eligible. Share with any doctor, forever.

30-Day Guarantee
Free Shipping
24/7 Support
HIPAA Compliant

Cookie & Privacy Preferences

HIPAA GDPR

We use cookies to ensure our website functions securely and to improve your experience. As a healthcare provider handling sensitive genetic data, we adhere to strict HIPAA and GDPR standards. No personal health information (PHI) is ever stored in cookies. You can customize your preferences below.

Privacy Policy